BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, Song G, Xiao C, Zhang X, Deng G, Wang R, Wang X. The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms. FEBS Open Bio 2021;11:1893-906. [PMID: 33728819 DOI: 10.1002/2211-5463.13146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Petrescu M, Vlaicu SI, Ciumărnean L, Milaciu MV, Mărginean C, Florea M, Vesa ȘC, Popa M. Chronic Inflammation—A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina 2022;58:641. [DOI: 10.3390/medicina58050641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Ma Y, Kan C, Qiu H, Liu Y, Hou N, Han F, Shi J, Sun X. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease. Front Pharmacol 2021;12:793586. [PMID: 34992540 DOI: 10.3389/fphar.2021.793586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]